

# MediGene AG



## Company Profile

**MediGene AG** is a publicly quoted German biopharmaceutical company headquartered in Martinsried, Munich, with subsidiary MediGene, Inc., in San Diego, California. MediGene combines a broad technology platform with products in pre-clinical and clinical development.


The company's multi-tiered business strategy has generated a number of proprietary enabling technologies to create a portfolio of novel therapeutic opportunities and drug candidates for in-house development and out-licensing.

## Stock Performance



Source: Bloomberg

## MediGene's Product Sale



## Key Stock Data

All figures in EURO, numbers as of 10.31.2001


Price	21.85
52 week high	116
52 week low	8.40
Shares outstanding (mil)	11.181
Market capitalization (mil)	244.30

Exchange

Neuer Markt


## Revenue Growth

thousands of EURO



## R&D Expenses

thousands of EURO



# MediGene AG



## Highlights:

- Revenues climbed by 23 % in the first half of 2001 to 2.85 million Euro in comparison with 2.31 million Euro in the same period of 2000.
- Loss of the period went up from -5.68 million Euro for the first half of 2000 to -10.93 million Euro for the first six months of 2001.
- EBIT amounted to -14.40 million Euro at the time of this report in comparison with -4.17 million Euro for the same period last year.
- The number of employees rose from 90 to 134 persons during the first half of the year.

## Management

- Dr. Peter Heinrich**  
Chief Executive Officer
- Dr. Johanna Holldack**  
Chief Operating Officer
- Angelika Heinz**  
Vice President, Head of Finance
- Dr. Thomas Henkel**  
Head of Research
- Dr. Frank Tufaro**  
Managing Director (MediGene, Inc.)

## Latest developments

- 11.05.2001 - **MediGene's Revenues Rise from Amendment of Schering Collaboration Agreement**
- 10.15.2001 - **Positive Phase 3 Data for MediGene's Polyphenon™E**
- 10.02.2001 - **MediGene cooperates with the German cancer research center**
- 09.18.2001 - **Broad US-patent issued to MediGene**

## New Products Coming to Market

Product (Indication)	Technology	Clinical Phase			Registration	Peak Sales Potential € MM / p.a. <sup>1)</sup>
		p2)	1	2		
Leuprogel™ (Prostate Cancer)	Atrigel®	[Progress bar from p2 to 3]				> 50
Polyphenon™E (Genital Warts)	NCE	[Progress bar from p2 to 3]				> 50
Etomoxir (Congestive Heart Failure)	NCE, ITD	[Progress bar from p2 to 2]				>> 500
G207 (Brain Tumors)	HSV		[Progress bar from p2 to 1]	start 2001		> 300
CVLP-Vaccine (Precursors of Cervical Cancer)	CVLP	[Progress bar from p2 to 1]				> 250
NV1020 (Liver Metastasis)	HSV	[Progress bar from p2 to 1]				> 200
rAAV-Vaccine (Malignant Melanoma)	rAAV	[Progress bar from p2 to 1]				> 200

## Analyst Coverage

- Dr. Steven Cox
- Commerzbank Securities**
- Dr. Andreas Bischof
- Credit Agricole Indosuez**
- Dr. Stephen McGarry
- Goldman Sachs International**
- Dr. Damian Pethica
- J.P.Morgan Chase H&Q Flemings**
- Dr. Daniel Mahony
- Morgan Stanley Dean Witter**

## MediGene AG

Dr. Peter Heinrich, CEO  
Lochamer Str. 11  
82152 Martinsried, Germany

Tel. 49-89-89 56 32-0  
Fax. 49-89-89 56 32-20

## Contact Information